{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T15:44:06Z","timestamp":1789487046635,"version":"build-2803163510"},"reference-count":49,"publisher":"Houston Methodist DeBakey Heart & Vascular Center","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,15]]},"DOI":"10.14797\/mdcvj.1860","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:42:33Z","timestamp":1789479753000},"page":"4-14","source":"Crossref","is-referenced-by-count":0,"title":["Familial Hypercholesterolemia"],"prefix":"10.14797","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7266-2762","authenticated-orcid":false,"given":"Iulia","family":"Iatan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2248-9663","authenticated-orcid":false,"given":"Jacques","family":"Genest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"5826","reference":[{"key":"key20260915134215_B1","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1001\/archinte.1939.00190040016002","article-title":"Angina pectoris in hereditary xanthomatosis","volume":"64","year":"1939","journal-title":"Arch Intern Med"},{"issue":"22","key":"key20260915134215_B2","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of Familial Hypercholesterolemia Among the General Population and Patients With Atherosclerotic Cardiovascular Disease: A Systematic Review and Meta-Analysis","volume":"141","year":"2020","journal-title":"Circulation"},{"issue":"20","key":"key20260915134215_B3","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects","volume":"75","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"key20260915134215_B4","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/jmg-2025-111201","article-title":"Frequency of familial hypercholesterolaemia-causing genetic variants in the 100 000 Genomes Project cohort: whole genome sequencing analyses of 77 260 participants","volume":"63","year":"2026","journal-title":"J Med Genet"},{"issue":"4","key":"key20260915134215_B5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1001\/jamacardio.2026.0006","article-title":"Management and Consequences of Genotype-Positive Familial Hypercholesterolemia","volume":"11","year":"2026","journal-title":"JAMA Cardiol"},{"issue":"45","key":"key20260915134215_B6","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"issue":"26","key":"key20260915134215_B7","article-title":"Update on familial hypercholesterolemia: An expert clinical consensus from the National Lipid Association","volume":"S1933-2874","year":"2026","journal-title":"J Clin Lipidol"},{"issue":"9","key":"key20260915134215_B8","first-page":"1210","article-title":"Simplified Canadian Definition for Familial Hypercholesterolemia","volume":"34","year":"2018","journal-title":"Can J Cardiol"},{"issue":"4746","key":"key20260915134215_B9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis","volume":"232","year":"1986","journal-title":"Science"},{"issue":"5","key":"key20260915134215_B10","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/ahg.12594","article-title":"Genetic Determinants of the Familial Hypercholesterolaemia Phenotype","volume":"89","year":"2025","journal-title":"Ann Hum Genet"},{"issue":"6787","key":"key20260915134215_B11","article-title":"The functional landscape of coding variation in the familial hypercholesterolemia gene LDLR","volume":"391","year":"2026","journal-title":"Science"},{"issue":"42","key":"key20260915134215_B12","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1093\/eurheartj\/ehaf190","article-title":"ESC\/EAS Scientific Document Group. 2025 Focused Update of the 2019 ESC\/EAS Guidelines for the management of dyslipidaemias","volume":"46","year":"2025","journal-title":"Eur Heart J"},{"issue":"11","key":"key20260915134215_B13","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1373\/clinchem.2014.225946","article-title":"Proprotein Convertase Subtilisin\/Kexin Type 9 (PCSK9): Lessons Learned from Patients with Hypercholesterolemia","volume":"60","year":"2014","journal-title":"Clin Chem"},{"issue":"19","key":"key20260915134215_B14","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1016\/j.jacc.2025.11.016","article-title":"2026 ACC\/AHA\/AACVPR\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","year":"2026","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"key20260915134215_B15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1001\/jamacardio.2023.5366","article-title":"Familial Hypercholesterolemia Variant and Cardiovascular Risk in Individuals with Elevated Cholesterol","volume":"9","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"11","key":"key20260915134215_B16","first-page":"2244","article-title":"Canadian and French Risk Scores Are Valid in Identifying Cardiovascular Disease in Australian Patients With Familial Hypercholesterolemia","volume":"41","year":"2025","journal-title":"Can J Cardiol"},{"issue":"12","key":"key20260915134215_B17","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/eurheartj\/ehae791","article-title":"Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry","volume":"46","year":"2025","journal-title":"Eur Heart J"},{"issue":"9540","key":"key20260915134215_B18","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/S0140-6736(06)69208-8","article-title":"Burden of valvular heart diseases: a population-based study","volume":"368","year":"2006","journal-title":"Lancet"},{"issue":"3","key":"key20260915134215_B19","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ijcard.2014.08.053","article-title":"The prevalence of aortic stenosis in the elderly in Iceland and predictions for the coming decades: the AGES-Reykjav\u00edk study","volume":"176","year":"2014","journal-title":"Int J Cardiol"},{"issue":"21","key":"key20260915134215_B20","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1093\/eurheartj\/ehad887","article-title":"Severe aortic stenosis: secular trends of incidence and outcomes","volume":"45","year":"2024","journal-title":"Eur Heart J"},{"issue":"22","key":"key20260915134215_B21","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/CIRCULATIONAHA.124.070982","article-title":"Rare Genetic Variants in LDLR, APOB, and PCSK9 Are Associated With Aortic Stenosis","volume":"150","year":"2024","journal-title":"Circulation"},{"issue":"1","key":"key20260915134215_B22","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/s41588-025-02417-6","article-title":"Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction","volume":"58","year":"2026","journal-title":"Nat Genet"},{"key":"key20260915134215_B23","article-title":"Aortic Stenosis in Familial Hypercholesterolemia: A Meta-Analysis","year":"2026"},{"issue":"10","key":"key20260915134215_B24","article-title":"Familial Hypercholesterolemia (FH) Registry Worldwide: A Systematic Review","volume":"47","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"key20260915134215_B25","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.atherosclerosis.2019.08.007","article-title":"Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry","volume":"289","year":"2019","journal-title":"Atherosclerosis"},{"issue":"17","key":"key20260915134215_B26","article-title":"Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial","volume":"14","year":"2025","journal-title":"J Am Heart Assoc"},{"issue":"10312","key":"key20260915134215_B27","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(21)01122-3","article-title":"Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)","volume":"398","year":"2021","journal-title":"Lancet"},{"issue":"22","key":"key20260915134215_B28","article-title":"Relative Efficacy of Alirocumab, Evolocumab, Inclisiran, and Bempedoic Acid on Lipids in Patients with Cardiovascular Disease or Familial Hypercholesterolaemia","volume":"14","year":"2025","journal-title":"J Clin Med"},{"issue":"3","key":"key20260915134215_B29","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41591-025-04179-4","article-title":"Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial","volume":"32","year":"2026","journal-title":"Nat Med"},{"issue":"2","key":"key20260915134215_B30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2025.20620","article-title":"Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial","volume":"335","year":"2026","journal-title":"JAMA"},{"issue":"1","key":"key20260915134215_B31","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jacl.2022.11.009","article-title":"Sex-related differences in premature cardiovascular disease in familial hypercholesterolemia","volume":"17","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"35","key":"key20260915134215_B32","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1093\/eurheartj\/ehae417","article-title":"Sex differences in treatment of familial hypercholesterolaemia: a meta-analysis","volume":"45","year":"2024","journal-title":"Eur Heart J"},{"issue":"3","key":"key20260915134215_B33","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/eurheartj\/ehaf592","article-title":"Statin use in pregnancy and risk of congenital malformations: a Norwegian nationwide study","volume":"47","year":"2026","journal-title":"Eur Heart J"},{"issue":"2","key":"key20260915134215_B34","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/MED.0000000000000954","article-title":"Familial hypercholesterolemia in pregnancy","volume":"33","year":"2026","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"key20260915134215_B35","article-title":"Extensive pregnancy-related off-treatment time in women with familial hypercholesterolaemia","volume":"415","year":"2026","journal-title":"Atherosclerosis"},{"issue":"25","key":"key20260915134215_B36","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1093\/eurheartj\/ehad197","article-title":"2023 Update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance","volume":"44","year":"2023","journal-title":"Eur Heart J"},{"issue":"4","key":"key20260915134215_B37","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jamacardio.2023.5597","article-title":"Sex Differences in Diagnosis, Treatment, and Cardiovascular Outcomes in Homozygous Familial Hypercholesterolemia","volume":"9","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"19","key":"key20260915134215_B38","first-page":"1898","article-title":"Homozygous Familial Hypercholesterolemia International Clinical Collaborators. Homozygous Familial Hypercholesterolemia Is a Life-Limiting Condition: Medical Life-Trajectories in the Post-2010 Era","volume":"85","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"key20260915134215_B39","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/MOL.0000000000000686","article-title":"Evidence for improved survival with treatment of homozygous familial hypercholesterolemia","volume":"31","year":"2020","journal-title":"Curr Opin Lipidol"},{"issue":"10326","key":"key20260915134215_B40","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(21)02001-8","article-title":"Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study","volume":"399","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"key20260915134215_B41","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/eurjpc\/zwab224","article-title":"Major adverse cardiovascular events in homozygous familial hypercholesterolaemia: a systematic review and meta-analysis","volume":"29","year":"2022","journal-title":"Eur J Prev Cardiol"},{"issue":"9","key":"key20260915134215_B42","article-title":"Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry","volume":"12","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"34","key":"key20260915134215_B43","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehac339","article-title":"Aortic stenosis in homozygous familial hypercholesterolaemia: a paradigm shift over a century","volume":"43","year":"2022","journal-title":"Eur Heart J"},{"issue":"20","key":"key20260915134215_B44","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1161\/CIRCULATIONAHA.111.042523","article-title":"Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy","volume":"124","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"key20260915134215_B45","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/eurjpc\/zwac028","article-title":"Understanding the efficacy and safety of lomitapide in homozygous familial hypercholesterolaemia","volume":"29","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"key20260915134215_B46","article-title":"Evinacumab with or without lipoprotein apheresis in homozygous familial hypercholesterolaemia","year":"2026","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"key20260915134215_B47","article-title":"Aortic Stenosis in Homozygous Familial Hypercholesterolemia","volume":"5","year":"2026","journal-title":"JACC Adv"},{"issue":"6","key":"key20260915134215_B48","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/MOL.0000000000001007","article-title":"Liver transplantation for homozygous familial hypercholesterolaemia","volume":"36","year":"2025","journal-title":"Curr Opin Lipidol"},{"issue":"35","key":"key20260915134215_B49","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1093\/eurheartj\/ehaf411","article-title":"Gene therapy and genome editing for lipoprotein disorders","volume":"46","year":"2025","journal-title":"Eur Heart J"}],"container-title":["Methodist DeBakey Cardiovascular Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T13:42:38Z","timestamp":1789479758000},"score":1,"resource":{"primary":{"URL":"https:\/\/journal.houstonmethodist.org\/articles\/10.14797\/mdcvj.1860\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,9,15]]}},"alternative-id":["10.14797\/mdcvj.1860"],"URL":"https:\/\/doi.org\/10.14797\/mdcvj.1860","relation":{},"ISSN":["1947-6108"],"issn-type":[{"value":"1947-6108","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]}}}